Physician profile
Mary F Scott
NPI 1487852372
$2,844.55
in general payments reported to CMS, 2019-2025
40 companies · $804 in 2025
The $804 reported for 2025 was more than what a typical Oncology (Clinical Nurse Specialist) provider received nationally (typical 2025 total: $263).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $339 · 2022: $639 · 2023: $457 · 2024: $606 · 2025: $804.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,867.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,866.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $491.25 | 2021-2025 | Opdivo |
| Daiichi Sankyo INC. | $249.75 | 2023-2025 | Enhertu |
| Gilead Sciences, INC. | $215.60 | 2022-2025 | Trodelvy |
| Incyte Corporation | $210.57 | 2021-2025 | Jakafi, Monjuvi, Pemazyre |
| Novartis Pharmaceuticals Corporation | $157.14 | 2022-2025 | |
| Kite Pharma, INC. | $118.27 | 2024-2025 | Yescarta |
| Janssen Biotech, INC. | $113.59 | 2022-2025 | Darzalex, Imbruvica, Talvey |
| Pfizer INC. | $104.03 | 2023-2025 | |
| Seagen INC. | $100.79 | 2021-2022 | |
| Astrazeneca Pharmaceuticals Lp | $95.87 | 2021-2025 | Enhertu |
| Celgene Corporation | $94.61 | 2022-2025 | Reblozyl |
| Stemline Therapeutics INC. | $81.55 | 2023-2025 | Orserdu |
| Beone Medicines USA, INC. | $76.48 | 2025 | Brukinsa, Tevimbra |
| Pharmacyclics LLC, An Abbvie Company | $68.08 | 2021-2023 | Imbruvica, Epkinly |
| Eisai INC. | $62.52 | 2022-2024 |
Show all 40 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Array Biopharma INC | $57.92 | 2023-2025 | Lorbrena, Braftovi, Mektovi |
| Astellas Pharma US INC | $46.60 | 2021-2025 | Xospata |
| Abbvie INC. | $45.81 | 2024 | |
| Glaxosmithkline, LLC. | $34.38 | 2025 | Ojjaara |
| Alexion Pharmaceuticals, INC. | $34.14 | 2023-2024 | Ultomiris |
| Lilly USA, LLC | $32.36 | 2021 | |
| Merck Sharp & Dohme LLC | $31.36 | 2022-2024 | Welireg, Keytruda, Reblozyl |
| Telix Pharmaceuticals | $24.56 | 2023 | Illuccix |
| Beigene USA, INC. | $23.10 | 2024 | Brukinsa |
| Genzyme Corporation | $22.48 | 2024 | |
| Ge Healthcare | $22.43 | 2022 | |
| Jazz Pharmaceuticals INC. | $20.48 | 2021 | |
| Geron Corporation | $20.39 | 2025 | Rytelo |
| Exelixis INC. | $19.36 | 2023 | Cabometyx |
| Puma Biotechnology, INC. | $18.73 | 2024 | |
| Dendreon Pharmaceuticals LLC | $17.85 | 2024 | Provenge |
| Pharmacosmos Therapeutics INC. | $17.80 | 2024 | Monoferric |
| Karyopharm Therapeutics INC. | $17.07 | 2022 | |
| Recordati_rare_diseases_inc. | $16.70 | 2025 | Sylvant |
| Genentech USA, INC. | $14.86 | 2023 | Tecentriq, Alecensa, Gavreto |
| G1 Therapeutics, INC. | $14.74 | 2022 | |
| Taiho Oncology, INC. | $14.45 | 2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $13.00 | 2021 | |
| Morphosys, US INC. | $11.99 | 2021 | |
| Epizyme, INC. | $11.89 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mary Scott listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.